Patrick Wood
Stock Analyst
(n/a)
# 2,132
Out of 4,648 analysts
67
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Overweight | $92 → $100 | $84.42 | +18.46% | 4 | Oct 24, 2024 | |
| EW Edwards Lifesciences | Reinstates: Equal-Weight | $70 | $66.45 | +5.34% | 7 | Oct 11, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $45 | $32.87 | +36.90% | 2 | Sep 23, 2024 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $95 → $104 | $104.68 | -0.65% | 4 | Sep 10, 2024 | |
| DXCM DexCom | Maintains: Equal-Weight | $120 → $75 | $69.83 | +7.41% | 6 | Jul 26, 2024 | |
| RBOT Vicarious Surgical | Maintains: Equal-Weight | $18 → $10 | $8.01 | +24.84% | 2 | Jul 15, 2024 | |
| GKOS Glaukos | Maintains: Equal-Weight | $100 → $120 | $132.44 | -9.39% | 2 | Jul 15, 2024 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $104 → $145 | $84.77 | +71.05% | 1 | Jul 15, 2024 | |
| SOLV Solventum | Maintains: Equal-Weight | $70 → $55 | $72.41 | -24.04% | 2 | Jul 15, 2024 | |
| ALC Alcon | Upgrades: Equal-Weight | $65 → $85 | $92.19 | -7.80% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $29.16 | +26.89% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $35.99 | -16.63% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $19.96 | -9.82% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $87.02 | -1.17% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $224.80 | -4.36% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $234.49 | +19.41% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $185 → $234 | $236.67 | -1.13% | 4 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $207.08 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $51.41 | -29.97% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $145.10 | - | 5 | Dec 11, 2017 |
Boston Scientific
Oct 24, 2024
Maintains: Overweight
Price Target: $92 → $100
Current: $84.42
Upside: +18.46%
Edwards Lifesciences
Oct 11, 2024
Reinstates: Equal-Weight
Price Target: $70
Current: $66.45
Upside: +5.34%
Tandem Diabetes Care
Sep 23, 2024
Maintains: Equal-Weight
Price Target: $45
Current: $32.87
Upside: +36.90%
The Cooper Companies
Sep 10, 2024
Maintains: Equal-Weight
Price Target: $95 → $104
Current: $104.68
Upside: -0.65%
DexCom
Jul 26, 2024
Maintains: Equal-Weight
Price Target: $120 → $75
Current: $69.83
Upside: +7.41%
Vicarious Surgical
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $8.01
Upside: +24.84%
Glaukos
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $100 → $120
Current: $132.44
Upside: -9.39%
TransMedics Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $84.77
Upside: +71.05%
Solventum
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $70 → $55
Current: $72.41
Upside: -24.04%
Alcon
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $92.19
Upside: -7.80%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $29.16
Upside: +26.89%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $35.99
Upside: -16.63%
May 6, 2024
Upgrades: Overweight
Price Target: $16 → $18
Current: $19.96
Upside: -9.82%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $87.02
Upside: -1.17%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $224.80
Upside: -4.36%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $234.49
Upside: +19.41%
Dec 4, 2023
Upgrades: Overweight
Price Target: $185 → $234
Current: $236.67
Upside: -1.13%
Dec 4, 2023
Upgrades: Overweight
Price Target: n/a
Current: $207.08
Upside: -
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $51.41
Upside: -29.97%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $145.10
Upside: -